LCAR-HL30

LCAR-HL30 is a **CD30-targeted chimeric antigen receptor T cell therapy (CAR-T)** designed to treat adults with **relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma**. The therapy utilizes genetically engineered autologous T cells expressing a synthetic receptor that binds specifically to **CD30 (Tumor necrosis factor receptor superfamily member 8)**, a protein expressed on malignant cells in these lymphomas. By targeting CD30, the engineered T cells can identify, bind, and destroy lymphoma cells. LCAR-HL30 is in Phase 1 clinical development, and studies are focused on assessing safety, tolerability, and preliminary efficacy in these patients[1][3][5][7][10]. The therapy was developed and is being tested in collaboration between Nanjing Legend Biotech and clinical centers in China. Mechanistically, it belongs broadly to **immunotherapy** and **cell therapy**, specifically leveraging the targeted cytotoxicity of CAR T cells[5].

Brand names

LCAR-HL30LCAR-HL-30LCAR-HL 30

Other names

CD30-Targeted LCAR-HL30 CellsCD-30-Targeted LCAR-HL30 CellsCD 30-Targeted LCAR-HL30 Cells